MSME (Udyam registered) Ministry of MSME
- Category
- Small (2024-25)
- Udyam number
- UDYAM-MH-19-0027245
PRIVATE_LIMITED.webp)
Lok-Beta Pharmaceuticals (India )Private Limited - pharma in Mumbai, Maharashtra, India. FY 2026 financials & compliance.
Revenue · FY 2024
₹60.2 Cr
▲ 40% YoY
Net profit · FY 2024
₹18.12 Lakh
Net margin 0.3%
EBITDA · FY 2024
₹5.55 Cr
EBITDA margin 9.2%
Authorised capital
₹1 Cr
Registered with MCA
Paid-up capital
₹30.66 Lakh
Issued & subscribed
Open charges
₹37.3 Cr
Satisfied ₹9.31 Cr
Company age
24 yrs
Est. 2002
Directors on board
4
As per MCA filings
About Lok-Beta Pharmaceuticals (India )Private Limited
Data last updated:
Lok-Beta Pharmaceuticals (India )Private Limited is a private limited company based in Mumbai, Maharashtra, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 18 April 2002 and has been in existence for over 24 years.
The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN U24230MH2002PTC135577. Its GSTIN is 27AAACL7288G1Z7 (Maharashtra). The company holds 2 GST registrations, all of them active.
The company has an authorised share capital of ₹1 Cr and a paid-up capital of ₹30.66 Lakh. It is led by directors including Alok Awadhesh Kumar (Managing Director) and Sudhanshu Kumar Singh.
Its last annual general meeting (AGM) was held on 30 September 2024, and its latest financial statements are for the year ended 31 March 2024. The registered office is at 324 Corporate Centre Nirmallifew Style Lbs Marg Mulund(W), Mumbai, Maharashtra, India – 400080.
As per the financials filed for FY 2024, the company reported a revenue of ₹60.2 Cr, a growth of 40% compared to the previous year. For the same year it recorded a net profit of ₹18.12 Lakh (net margin 0.3%) and EBITDA of ₹5.55 Cr (EBITDA margin 9.2%). Revenue has grown at a compounded annual rate (CAGR) of 13% over three years and 7% over five years.
As per MCA filings, the company has open charges of ₹37.3 Cr and satisfied charges of ₹9.31 Cr on record. Court records list 2 cases involving the company, including 2 filed by the company. The company has 4 deals on record (2 funding rounds, 1 rights issue, 1 secondary share transfer), with disclosed funding of ₹3.49 Cr; the latest was in March 2017. Its 5 peer companies in the Pharma industry (Formulations, Pharmaceuticals), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 2 larger and 3 smaller; the largest is Yacca Lifesciences Private Limited with revenue of ₹60.81 Cr.
Lok-Beta Pharmaceuticals (India )Private Limited is registered as a small enterprise under the Udyam registration framework (Reg. No. UDYAM-MH-19-0027245). The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website lokbeta.in.
Company details
CIN U24230MH2002PTC135577
Registration Number 135577
Incorporation Date 18 April 2002
ROC Mumbai
Listing Status Unlisted
Company Status Active
Date of Last AGM 30 September 2024
Date of Balance Sheet 31 March 2024
Compliance Status Active Compliant
MSME Classification Small
Udyam Registration UDYAM-MH-19-0027245
Recognitions & Rankings of Lok-Beta Pharmaceuticals (India )
Contact details
Lok-Beta Pharmaceuticals (India )Private Limited's registered office is in Mumbai, Maharashtra. Its website is lokbeta.in. Its e-mail address is in the company report.
- Email
- Website
- Social Media
- Registered Address324 Corporate Centre Nirmallifew Style Lbs Marg Mulund(W), Mumbai, Maharashtra, India – 400080
- IndustryPharma, Drug Formulation & Development
To see the full contact details of Lok-Beta Pharmaceuticals (India )Private Limited, buy the company report.
Comprehensive company report
Lok-Beta Pharmaceuticals (India )Private Limited - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Business activity
The main business activity of Lok-Beta Pharmaceuticals (India ) is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
To see the full business activity and turnover split of Lok-Beta Pharmaceuticals (India )Private Limited, buy the company report.
Financials of Lok-Beta Pharmaceuticals (India )Private Limited
FY 2024 filings availableLok-Beta Pharmaceuticals (India )Private Limited reported revenue of ₹60.2 Cr (up 40% YoY) for FY 2024.
Revenue · FY 2024
₹60.2 Cr ▲ 40%
Net profit · FY 2024
₹18.12 Lakh margin 0.3%
EBITDA · FY 2024
₹5.55 Cr margin 9.2%
Compounded Annual Growth Rate (CAGR)
Revenue CAGR growth
1 year
▲ 40%
3 years · compounded
▼ 13%
5 years · compounded
▲ 7%
EBITDA CAGR growth
1 year
▼ 20%
3 years · compounded
▼ 9%
5 years · compounded
▲ 12%
Revenue has grown at a compounded annual rate (CAGR) of 7% over five years, including 40% growth in the latest year. EBITDA fell 20% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹5.55 Cr | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | ₹18.12 Lakh | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 9.2% | ||||
| Net Profit Margin | 0.3% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Lok-Beta Pharmaceuticals (India )Private Limited, buy the company report.
Board of directors of Lok-Beta Pharmaceuticals (India )Private Limited
Lok-Beta Pharmaceuticals (India ) has 4 current directors and 5 former directors. Current directors are listed first, with their designation and appointment date.
Current Directors
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Sudhanshu Kumar Singh Also directs: J Duncan Healthcare Private Limited | Director | 22 Aug 2012 | 14 Years 2 Months | Current |
| Hina Kiran | Director | 01 Oct 2014 | 12 Years 0 Months | Current |
| Alok Awadhesh Kumar | Managing Director | 18 Apr 2002 | 24 Years 6 Months | Current |
| Ashish Kumar | Director | 01 Dec 2022 | 3 Years 10 Months | Current |
Peer comparison
Lok-Beta Pharmaceuticals (India )Private Limited is compared with the 5 companies closest to it by revenue in the Pharma industry (Formulations, Pharmaceuticals), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Yacca Lifesciences Private Limited | ₹60.81 Cr (FY 2024) | 39.0% | Roorkee, Uttarakhand, India | |||
| Kausikh Therapeutics Private Limited | ₹60.69 Cr (FY 2025) | 8.0% | Gerugambakkam, Tamil Nadu, India | |||
| Lok-Beta Pharmaceuticals (India )Private Limitedthis company | ₹60.2 Cr (FY 2024) | ₹18.12 Lakh | 0.3% | 40.0% | Mumbai, Maharashtra, India | |
| Deccan Health Care Limited | ₹59.74 Cr (FY 2024) | 33.0% | Hyderabad, Telangana, India | |||
| Systole Remedies Private Limited | ₹59.68 Cr (FY 2025) | 28.0% | Delhi, India | |||
| Parb Pharmaceuticals Private Limited | ₹59.42 Cr (FY 2025) | 2461.0% | Dehradun, Uttarakhand, India |
To see the full peer comparison of Lok-Beta Pharmaceuticals (India )Private Limited, buy the company report.
Auditor
Lok-Beta Pharmaceuticals (India )Private Limited is audited by RAJU & PRASAD for the financial year 2021.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| RAJU & PRASAD | FY 2021 | 003475S |
Shareholding
The shareholding of Lok-Beta Pharmaceuticals (India )Private Limited is on record for 5 financial years, the latest being FY 2021, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|
| Promoters | |||||
| Domestic institutional investors (DII) | |||||
| Foreign institutional investors (FII) | |||||
| Public | |||||
| Others |
To see the full shareholding pattern of Lok-Beta Pharmaceuticals (India )Private Limited, buy the company report.
Charges & borrowings
Open charges
₹37.3 Cr
Satisfied charges
₹9.31 Cr
Breakdown by lending institutions
Latest charge details
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 25 May 2022 | 100583548 | Axis Bank Limited | ₹2.24 Cr | Open | |
| 22 Apr 2022 | 100582327 | Axis Bank Limited | ₹2.15 Cr | Open | |
| 26 Mar 2021 | 100428969 | State Bank of India | ₹2.4 Cr | Open | |
| 17 Feb 2021 | 100421575 | Axis Bank Limited | ₹10 Cr | Open | |
| 08 Jan 2021 | 100411225 | Axis Bank Limited | ₹1.24 Cr | Open |
To see the full charge records of Lok-Beta Pharmaceuticals (India )Private Limited, buy the company report.
Total charge records: 8 View all charges
Deals & funding
Lok-Beta Pharmaceuticals (India )Private Limited has 4 deals on record (2 funding rounds, 1 rights issue, 1 secondary share transfer), with disclosed funding of ₹3.49 Cr; the latest was in March 2017.
Total deals
4
Funding rounds
2
Rights issue
1
Secondary share transfer
1
Disclosed funding
₹3.49 Cr
Deals on record (4 of 4)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Mar 2017 | Rights issue | ₹40 Lakh | Investors: an individual |
| Mar 2013 | Funding round | ₹3.4 Cr | Investors: J Duncan Healthcare Private Limited , 2 individuals |
| Mar 2012 | Secondary share transfer | Undisclosed | Buyer: 2 individuals Seller: an individual |
| Jun 2007 | Funding round | ₹9.8 Lakh | Investors: an individual |
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Lok-Beta Pharmaceuticals (India )Private Limited has 2 court cases on record: 2 filed by Lok-Beta Pharmaceuticals (India ). All cases are disposed.
Total cases
2
Filed by the company
2
Disposed
2
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| High courts | 2 | 0 | 0 |
Cases on record (2 of 2)
| Court | Type of case | Party | Status |
|---|---|---|---|
| Bombay High Court | Appeal | Filed by the company against Emprocell Clinical Research Private Limited Cin No. U24231mh2006ptc161334 | Disposed |
| Bombay High Court | Company petition | Filed by the company against Emprocell Clinical Research Private Limited Cin No. U24231mh2006ptc161334 | Disposed |
To see the full case history of Lok-Beta Pharmaceuticals (India )Private Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Lok-Beta Pharmaceuticals (India )Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
Group structure & subsidiaries
Lok-Beta Pharmaceuticals (India ) has 1 associated company. This group structure data is as of FY 2021. The table lists each entity with its relationship and holding.
1
Associated companies
GST
Lok-Beta Pharmaceuticals (India ) has 2 GST registrations: 2 active.
Total GSTINs
2
Active
2
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 27AAACL7288G1Z7 | Maharashtra | Active | 01 Jul 2017 |
| 30AAACL7288G1ZK | Goa | Active | 17 May 2018 |
To see the full GST registrations and return filing status of Lok-Beta Pharmaceuticals (India )Private Limited, buy the company report.
Recent activity
Lok-Beta Pharmaceuticals (India )Private Limited has 9 board changes on record since 2002: 4 appointments and 5 cessations. The latest: Ashish Kumar was appointed as Director on 01 Dec 2022.
AGM
Lok-Beta Pharmaceuticals (India )Private Limited last Annual general meeting of members was held on 30 Sep 2024 as per latest MCA records.
Filing
Lok-Beta Pharmaceuticals (India )Private Limited has filed its annual Financial statements for the year ended 31 Mar 2024 with Roc Mumbai.
Appointed
Ashish Kumar was appointed as Director.
Charges
A charge with Axis Bank Limited amounted to Rs. 2.24 Cr with Charge ID 100583548 was registered on 25 May 2022.
Charges
A charge with Axis Bank Limited of Rs. 2.15 Cr registered on 22 Apr 2022 with Charge ID 100582327 was modified on 25 May 2022.
Charges
A charge with Axis Bank Limited amounted to Rs. 2.15 Cr with Charge ID 100582327 was registered on 22 Apr 2022.
Ceased
Hina Kiran ceased to be Director.
Charges
A charge with State Bank Of India amounted to Rs. 2.40 Cr with Charge ID 100428969 was registered on 26 Mar 2021.
Charges
A charge with Axis Bank Limited amounted to Rs. 10.00 Cr with Charge ID 100421575 was registered on 17 Feb 2021.
Charges
A charge with Axis Bank Limited of Rs. 3.27 Cr registered on 29 Oct 2020 with Charge ID 100388944 was modified on 17 Feb 2021.
Charges
A charge with Axis Bank Limited amounted to Rs. 1.24 Cr with Charge ID 100411225 was registered on 08 Jan 2021.
Charges
A charge with Axis Bank Limited amounted to Rs. 3.27 Cr with Charge ID 100388944 was registered on 29 Oct 2020.
13 earlier events are in the company report.
Frequently asked questions
Lok-Beta Pharmaceuticals (India ) is an active private limited company based in Mumbai, Maharashtra, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 18 April 2002 (24+ years old) and is registered under CIN U24230MH2002PTC135577.
Lok-Beta Pharmaceuticals (India ) has 4 current directors:
- Alok Awadhesh Kumar - Managing Director
- Sudhanshu Kumar Singh - Director
- Hina Kiran - Director
- Ashish Kumar - Director
The latest financial statements of Lok-Beta Pharmaceuticals (India ) on record with the MCA are for the year ended 31 March 2024. Its last annual general meeting was held on 30 September 2024. Year-wise statements from 2015 are in the company report.
The GSTIN of Lok-Beta Pharmaceuticals (India ) is 27AAACL7288G1Z7, registered in Maharashtra. The company has 2 GST registrations in all, of which 2 are active. Other active GSTINs include 30AAACL7288G1ZK (Goa).
The CIN (Corporate Identification Number) of Lok-Beta Pharmaceuticals (India ) is U24230MH2002PTC135577. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Lok-Beta Pharmaceuticals (India ) has 2 court cases on record: 2 filed by the company.
Lok-Beta Pharmaceuticals (India ) was incorporated on 18 April 2002, making it 24+ years old. It is registered with the Registrar of Companies, Mumbai.
Lok-Beta Pharmaceuticals (India ) has 4 deals on record (2 funding rounds, 1 rights issue, 1 secondary share transfer), with disclosed funding of ₹3.49 Cr; the latest was in March 2017.
The peers of Lok-Beta Pharmaceuticals (India ) by revenue are Yacca Lifesciences Private Limited, Kausikh Therapeutics Private Limited, Deccan Health Care Limited, Systole Remedies Private Limited, Parb Pharmaceuticals Private Limited, all in the Pharma industry (Formulations, Pharmaceuticals), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).
Ashish Kumar was appointed as Director on 01 Dec 2022. Hina Kiran ceased to be Director on 01 Apr 2022. Rina Singh ceased to be Additional Director on 12 Aug 2020. Lok-Beta Pharmaceuticals (India ) has 9 board changes on record in total.
Yes, Lok-Beta Pharmaceuticals (India ) is registered as a small enterprise under Udyam registration (number: UDYAM-MH-19-0027245).
Sample company reports
The same report you get when you buy one: financials, directors, ownership, deals, charges, legal cases, brands and filings, with the Excel workbook alongside.
Swiggy Limited Listed company · 92 pages
BharatPe (Resilient Innovations Pvt Ltd) Unlisted company · 78 pages